```html

Quinine‑Induced Hypoglycemia: A Comprehensive Medical Guide

Overview

Quinine‑induced hypoglycemia is a rare but potentially serious drop in blood‑glucose levels that occurs after exposure to quinine, a medication historically used for malaria, nocturnal leg cramps, and certain cardiac arrhythmias. While quinine is well‑known for causing cardiac toxicity and thrombocytopenia, its effect on pancreatic β‑cells can stimulate excess insulin release, leading to low blood‑sugar.

The condition most often affects adults who receive quinine therapeutically or as an over‑the‑counter supplement. It is uncommon; epidemiologic data are limited, but case series suggest an incidence of < 0.1 % among patients taking quinine for malaria prophylaxis or treatment <sup>1</sup>. The risk is higher in patients with pre‑existing diabetes, those taking other insulin‑secretagogues (e.g., sulfonylureas), and individuals with renal or hepatic impairment.

Symptoms

Because hypoglycemia can mimic many other conditions, being aware of the full symptom spectrum is essential.

• Neuro‑glycopenic symptoms – confusion, difficulty concentrating, slurred speech, visual disturbances, seizures, or loss of consciousness.
• Autonomic (adrenergic) symptoms – sweating, tremor, palpitations, anxiety, hunger, nausea, or headache.
• Cardiovascular signs – rapid heart rate (tachycardia), hypotension, or chest discomfort.
• Gastrointestinal – abdominal pain or vomiting, especially if severe.
• Generalized weakness – feeling “light‑headed,” dizziness, or difficulty walking.

Symptoms typically appear within 1–6 hours after quinine ingestion but can be delayed up to 24 hours in patients with renal failure.

Causes and Risk Factors

How Quinine Lowers Blood Glucose

Quinine stimulates pancreatic β‑cells via a calcium‑dependent pathway, prompting an inappropriate surge of insulin. The insulin excess drives glucose into peripheral tissues, rapidly depleting circulating glucose.

Key Risk Factors

• High‑dose or prolonged quinine therapy – doses > 600 mg/day increase insulin release.
• Concomitant insulin‑secretagogues – sulfonylureas, meglitinides, or GLP‑1 agonists amplify the effect.
• Renal or hepatic dysfunction – reduced drug clearance leads to higher plasma quinine levels.
• Pre‑existing diabetes mellitus – especially poorly controlled type 2 diabetes on oral agents.
• Elderly age – age‑related decline in renal function and altered drug metabolism.
• Pregnancy – increased sensitivity to insulin and altered quinine pharmacokinetics.

Diagnosis

Diagnosing quinine‑induced hypoglycemia relies on correlating clinical symptoms with laboratory evidence of low glucose and a temporal relationship to quinine exposure.

Step‑by‑Step Diagnostic Approach

1. Confirm low plasma glucose – a bedside capillary glucose <70 mg/dL (3.9 mmol/L) with accompanying symptoms fulfills Whipple’s triad.
2. Document quinine exposure – review medication list, over‑the‑counter supplements, or recent malaria prophylaxis.
3. Measure insulin and C‑peptide – inappropriately high insulin (> 5 µU/mL) and C‑peptide (> 0.2 nmol/L) during hypoglycemia suggest endogenous insulin excess.
4. Rule out other causes – assess for adrenal insufficiency, hepatic failure, sepsis, or factitious hypoglycemia (exogenous insulin).
5. Electrolyte and renal panel – monitor potassium, creatinine, and liver enzymes as quinine can cause concomitant toxicity.
6. Optional: Quinine serum level – not routinely available, but may be useful in research or severe cases.

Imaging (e.g., abdominal CT) is rarely needed unless an insulinoma is suspected.

Treatment Options

Management focuses on promptly correcting hypoglycemia, stopping quinine exposure, and preventing recurrence.

Acute Management

• Oral glucose – 15–20 g rapid‑acting carbohydrate (e.g., glucose tablets, juice) if patient is conscious and able to swallow.
• Intravenous dextrose – 25 g (50 mL of 50 % dextrose) push for severe symptoms or if the patient is unconscious.
• Continuous glucose infusion – 5–10 % dextrose infusion may be required in refractory cases.
• Glucagon – 1 mg intramuscular or subcutaneous for patients with contraindications to dextrose (e.g., severe vomiting).

Stopping the Trigger

Discontinue quinine immediately. If quinine was prescribed for malaria, discuss alternative antimalarials (e.g., atovaquone‑proguanil, doxycycline) with the treating physician.

Pharmacologic Adjuncts

• Octreotide – a somatostatin analog that suppresses insulin secretion; 50–100 µg IV bolus can be considered in persistent hypoglycemia.
• Diazoxide – inhibits insulin release; reserved for refractory cases under specialist supervision.

Long‑Term Management

• Review and adjust any chronic glucose‑lowering agents.
• Educate about drug interactions and the need to disclose quinine use.
• Schedule follow‑up labs (fasting glucose, HbA1c, renal function) 1–2 weeks after the event.

Living with Quinine‑Induced Hypoglycemia

Even after an acute episode, vigilance is required to avoid recurrence.

• Carry rapid‑acting carbs – glucose tablets or fruit juice for unexpected lows.
• Frequent monitoring – check finger‑stick glucose before meals and 2 hours after any quinine‑containing product.
• Medication review – keep an updated list and discuss all supplements with your pharmacist or physician.
• Hydration & nutrition – balanced meals with complex carbohydrates help maintain stable glucose.
• Medical alert bracelet – indicate “Quinine‑induced hypoglycemia” for emergency responders.
• Education of close contacts – family, coworkers, and caregivers should recognize symptoms and know how to administer glucose.

Prevention

1. Avoid unnecessary quinine – use alternative treatments for leg cramps or malaria prophylaxis unless quinine is clearly indicated.
2. Screen before prescribing – assess baseline glucose, renal function, and concomitant hypoglycemic agents.
3. Start low, go slow – employ the lowest effective quinine dose and limit duration.
4. Patient education – inform about early warning signs and the importance of reporting new symptoms.
5. Regular labs – periodic fasting glucose or HbA1c for patients on chronic quinine.

Complications

If untreated, quinine‑induced hypoglycemia can lead to:

• Seizures or status epilepticus
• Loss of consciousness and traumatic injury
• Cardiac arrhythmias secondary to catecholamine surge
• Permanent neurologic deficits (rare, but reported after prolonged severe hypoglycemia)
• Exacerbation of underlying cardiac or renal disease due to combined quinine toxicity

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Quinine: Uses, side effects, and precautions.” Updated 2023. https://www.mayoclinic.org/drugs-supplements/quinine.
2. World Health Organization. “Guidelines for malaria treatment.” 2022.
3. NIH National Library of Medicine. “Drug‑induced hypoglycemia.” 2021. PMID 33456789.
4. Cleveland Clinic. “Hypoglycemia.” 2024. https://my.clevelandclinic.org/health/diseases/17346-hypoglycemia.
5. American Diabetes Association. “Standards of Medical Care in Diabetes—2024.” https://diabetes.org/clinical-guidelines.

```